Series C+

Basel-based biotech Nouscom just raised €120 million to fund a pivotal trial for NOUS-209, shifting oncology from treating tumors to intercepting them entirely.

With a new $125M Series D, Medical Microinstruments is moving robotics into the sub-millimeter realm, targeting lymphatic repair and Alzheimer's disease.

Menlo Ventures backs Factory at a massive $5 billion valuation. Let's crunch the numbers on why autonomous software is tech's next major frontier.

As AI moves from hype to production, investors are betting billions on the unglamorous but critical infrastructure that makes it all work. Here's why.

Hermeus unveils Ramjet-X, a low-cost test vehicle. But the real story is its 'Flight Test as a Service' model, poised to slash costs and accelerate the high-speed race.

Canadian fintech investment nears $1B, but the story isn't the total. It's a strategic shift to fewer, bigger bets on companies with proven AI and scale.

With a new $100M funding round, Rillet is challenging ERP giants by building an 'Accounting Superintelligence' where AI agents and humans run finance together.

A simple urine test could soon detect cancer early. With $33M in fresh funding, Japanese bio-AI firm Craif is betting its tech can change U.S. healthcare.

A new AI agent from Assort Health is automating the chaotic patient referral process, promising to recover lost revenue and get patients to care faster.

With a fresh $50M, travel tech firm Faye is betting on AI to resolve claims before your vacation is over. But can technology truly automate peace of mind?

As enterprises deploy autonomous AI agents, a new billion-dollar security risk emerges. Obsidian Security's unicorn status reveals a critical new frontier.

Following an $11B valuation, AI inference leader SambaNova hires a veteran dealmaker to accelerate its push into the high-stakes government and sovereign AI markets.

With a fresh $250M in funding, Horizon3 is leading the charge in proactive security, proving that the future of cyber defense isn't just about building walls, but about deploying AI hackers to tear them down first.

With a fresh $550M, Antora Energy is scaling its thermal batteries to solve America's energy crunch, promising cheap, clean power for industry and data centers.

Forget autonomous factories. The real money in manufacturing AI is flowing to systems that prioritize human trust and oversight. Here's who's winning.

With key hires in finance, regulatory, and manufacturing, Cyllene Therapeutics signals it's preparing for the big leagues. But can it deliver?

Peregrine Technologies' appointment of Adrian Kaplan isn't just a new hire; it's a calculated move to mature its financial operations for global scale.

With $9M in new funding, Trellis Bioscience advances a novel antibody that shatters bacterial defenses, offering hope for devastating joint infections.

With a $70M Series C and unique 3D printing tech, SWISSto12 proves the new space economy is moving beyond hype to sustainable, profitable infrastructure.

Emergent's massive Series C and unicorn status signal a new frontier for SMBs. But can its "agentic AI" truly deliver production-ready software, or do hidden costs and technical risks remain?